Synergistic Inhibition of Human Immunodeficiency Virus Replication In Vitro by Combinations of 3′-Azido-3′-Deoxythymidine and 3′-Fluoro-3′-Deoxythymidine
- 1 October 1990
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 6 (10) , 1197-1202
- https://doi.org/10.1089/aid.1990.6.1197
Abstract
The antiviral activity against human immunodeficiency virus type 1 of the two structurally related thymidine analogs azidothymidine and fluorothymidine, both alone and in combination, was tested. Fluorothymidine was tenfold more active than azidothymidine. The selectivity indices of the two compounds were similar. The combination of azidothymidine and fluorothymidine showed clearly synergistic antiviral activity, and diminished cytotoxicity. The inhibition of reverse transcriptase from human immunodeficiency virus type 1 by the triphosphates of azidothymidine and fluorothymidine, both alone and in combination was also tested. Azidothymidine triphosphate was a fourfold stronger inhibitor than fluorothymidine triphosphate. The combination of the two showed only additive (and not synergistic) effects upon reverse transcriptase. The combination of azidothymidine and fluorothymidine showed both synergistic antiviral activity and diminished cytotoxicity, and may therefore represent a promising therapeutic strategy. The additive (and not synergistic) inhibition of reverse transcriptase by the combination of the triphosphate indicates that in cell culture additional factors other than inhibition of the reverse transcriptase by the triphosphates influence the antiviral activity of the combination. Such factors might include effects upon normal nucleoside metabolism or metabolism of the analogs. Alternatively, one of the nucleosides might have an additional mechanism of action besides inhibition of the reverse transcriptase.This publication has 18 references indexed in Scilit:
- Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1Antimicrobial Agents and Chemotherapy, 1989
- Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cellsBiochemical and Biophysical Research Communications, 1988
- Phosphorylation, anti-HIV activity and cytotoxicity of 3′-fluorothymidineBiochemical and Biophysical Research Communications, 1988
- Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5′-triphosphate in comparison to cellular DNA polymerases α and βBiochemical and Biophysical Research Communications, 1987
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Inhibition of the reverse transcriptase from HIV by 3′-azido-3′-deoxythymidine triphosphate and its threo analogueAntiviral Research, 1987
- PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1986
- Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDSScience, 1984
- Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDSScience, 1984
- Analysis of combined drug effects: a new look at a very old problemTrends in Pharmacological Sciences, 1983